The first cancer virotherapy medicine
RIGVIR® contains a live non-pathogenic ECHO-7 virus that has not been genetically modified. RIGVIR® is oncolytic and oncotropic. It finds and selectively infects tumour cells.
Oncolytic virotherapy with RIGVIR® is a safe and effective cancer treatment, which improves progression time, survival and the quality of life of cancer patients. RIGVIR® is well tolerated and does not cause serious adverse effects. The most common side effect is a subfebrile temperature for 1-3 days. This is reversible and does not require treatment.
RIGVIR® is the first oncolytic virotherapy medicine that has been approved for cancer treatment and that has been introduced into medical practice. RIGVIR® was approved in Latvia in 2004 for cutaneous melanoma therapy. Since 2011 RIGVIR® is fully reimbursed by the state for residents of Latvia and from 2015 it has been included in the guidelines for skin cancer and melanoma treatment. In 2015 RIGVIR® was approved in Georgia, since 2016 it has been approved in Armenia, but since 2018 – in Uzbekistan.